Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
88.15
+2.19 (2.55%)
Oct 15, 2025, 4:00 PM EDT - Market closed
Incyte Revenue
Incyte had revenue of $1.22B in the quarter ending June 30, 2025, with 16.46% growth. This brings the company's revenue in the last twelve months to $4.58B, up 18.87% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.58B
Revenue Growth
+18.87%
P/S Ratio
3.72
Revenue / Employee
$1,752,005
Employees
2,617
Market Cap
17.21B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
INCY News
- 13 hours ago - 3 Biotech Stocks I Am Accumulating - Seeking Alpha
- 3 days ago - Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 - Business Wire
- 7 days ago - Incyte to Report Third Quarter Financial Results - Business Wire
- 9 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 18 days ago - China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewsWire
- 21 days ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Cramer reveals 5 undervalued stocks that are must-own heading into 2026 - Invezz
- 23 days ago - Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher - CNBC